First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Omid HamidAlberto A ChiapporiJohn A ThompsonToshihiko DoiSiwen Hu-LieskovanFerry A L M EskensWilleke RosAdi DiabJean-Philippe SpanoNaiyer A RizviJeffrey S WasserEric AngevinPatrick A OttAlison ForgieWenjing YangCen GuoJeffrey ChouAnthony B El-KhoueiryPublished in: Journal for immunotherapy of cancer (2022)
NCT02315066.